IETDC
IETDC is a caspase 8-responsive fluorescent probe. IETDC is cleaved by activated caspase 8 to release D-cysteine, which then reacts with 6-hydroxy-2-cyanobenzothiazole (HCBT) to form firefly luciferin in situ. IETDC must be used in conjunction with PCL-2 (HY-D3168) to detect the co-existence of hydrogen peroxide and caspase 8. IETDC is applicable to studies related to acute inflammation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1476735-95-1
- Formule: C32H47N5O13S
- Masse moléculaire:741.81
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
Description
IC50 & Target
[1]|
Caspase-8 |
In Vitro
IETDC (5 μM; 60 min) is selectively cleaved by recombinant caspase 8 but not caspase 3 or caspase 9 to release D-cysteine, which forms luciferin with HCBT to produce a ca. 27-fold increase in bioluminescent signal, and this response is fully inhibited by a pan-caspase inhibitor[1].
IETDC (10 μM; 60 min) acts as part of an AND-type molecular logic gate, producing an ca. 18-fold increase in bioluminescent signal only when combined with PCL-2, hydrogen peroxide, and active caspase 8, with signal blocked by inhibition of either hydrogen peroxide-mediated PCL-2 cleavage or caspase 8-mediated IETDC cleavage[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
IETDC (0.05 μmol; i.p.; single dose), co-administered with PCL-2, produces a 2.7-fold bioluminescent signal increase in female FVB-luc+ mice with LPS (HY-D1056)-induced acute inflammation, which is 30% attenuated by co-treatment with ascorbic acid and a pan-caspase inhibitor[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:FVB-luc+ (female, 2-5 months old)[1]
-
Dosage:0.05 μmol (co-administered with 0.05 μmol HCBT)
-
Administration:i.p.; single dose
-
Result:Produced an 18-fold increase in bioluminescent signal in lipopolysaccharide-treated mice compared to saline-treated controls.
Caused a 34% attenuation of the elevated bioluminescent signal when pre-treated with z-VD(OMe)-OPh.
-
Animal Model:FVB-luc+ (female, 2-5 months old)[1]
-
Dosage:0.05 μmol (co-administered with 0.05 μmol PCL-2)
-
Administration:i.p.; single dose
-
Result:Produced a 2.7-fold increase in bioluminescent signal in lipopolysaccharide-treated mice compared to saline-treated controls.
Caused a 30% attenuation of the elevated bioluminescent signal when co-treated with ascorbic acid and z-VD(OMe)-OPh.
Chemical Information
-
CAS No. 1476735-95-1
-
Masse moléculaire 741.81
-
Formule C32H47N5O13S
-
Sequence
Cbz-Ile-{Glu(Me)}-Thr-{Asp(Me)}-{d-Cys}
-
Sequence Shortening
Cbz-I-{Glu(Me)}-T-{Asp(Me)}-{d-Cys}
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
Zymosan-Induced Peritonitis
Zymosan-induced peritonitis is a sterile acute-inflammation model produced by intraperitoneal injection of zymosan, a yeast cell-wall particle preparation, followed by quantification of leukocyte recruitment and soluble inflammatory mediators in peritoneal lavage fluid. Low-dose zymosan peritonitis is commonly used as a self-resolving acute inflammation model in which neutrophil recruitment occurs early and monocyte/macrophage accumulation follows later. The assay readouts include total peritoneal leukocyte number, differential neutrophil and monocyte/macrophage counts, peritoneal cytokines and chemokines, plasma or peritoneal exudation, and optional lipidomic or metabolomic changes during inflammation and resolution. Early neutrophil recruitment after zymosan depends strongly on complement and mast-cell C5a receptor signaling, whereas later monocyte recruitment is linked to MCP-1/CCL2 production.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)